NTRK1 and neoplasm: The investigators hypothesized that these effects are mediated by inhibition of MerTK, a tyrosine kinase receptor that when activated contributes to an immune tolerant tumor microenvironment via the regulation of phagocytosis by tumor‐associated macrophages.